As the coronavirus disease 2019 (COVID-19) pandemic grows, accumulating evidence suggests that patients with cancer have increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent morbidity and mortality.1- 3 Further, COVID-19 may be asymptomatic.4 Despite limited evidence, the European Society for Medical Oncology recommends universal microbiologic SARS-CoV-2 screening for patients undergoing active anticancer therapy.5 To identify asymptomatic COVID-19, we implemented universal microbiologic screening for SARS-CoV-2 for all asymptomatic patients with cancer prior to anticancer therapy at Alzahra Hospital Dubai, United Arab Emirates (UAE).
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Humaid O. Al-Shamsi, MD, MRCP, University of Sharjah, University City Road, PO Box 27272, Sharjah. United Arab Emirates (firstname.lastname@example.org).
Accepted for Publication: May 11, 2020.
Published Online: May 27, 2020. doi:10.1001/jamaoncol.2020.2548
Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2020 Al-Shamsi HO et al. JAMA Oncology.
Author Contributions: Drs Al-Shamsi and Alrawi had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Al-Shamsi.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Al-Shamsi, Coomes.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Al-Shamsi, Coomes.
Obtained funding: Al-Shamsi.
Administrative, technical, or material support: Al-Shamsi, Alrawi.
Supervision: Al-Shamsi, Alrawi.
Conflict of Interest Disclosures: Dr Al-Shamsi received publication funding from Roche Pharmaceuticals Middle East FZCO. Dr Coomes reports grants from Toronto COVID-19 Action Fund outside the submitted work; and Dr Coomes has submitted applications as a coprincipal investigator on a randomized clinical trial for chemoprophylaxis for COVID-19. No other conflicts are reported.
Funding/Support: Roche Pharmaceuticals Middle East FZCO, Dubai, United Arab Emirates. Roche Pharmaceuticals provided funding for open-access publication.
Role of the Funder/Sponsor: Roche Pharmaceuticals had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank all patients and their families who were enrolled in this study.
You currently have no searches saved.
You currently have no courses saved.